Poseida Therapeutics, Inc. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported revenue was USD 20.01 million compared to USD 2.7 million a year ago. Net loss was USD 27.46 million compared to USD 43.04 million a year ago. Basic loss per share from continuing operations was USD 0.32 compared to USD 0.69 a year ago.
For the six months, revenue was USD 30.36 million compared to USD 4.14 million a year ago. Net loss was USD 66.3 million compared to USD 101.09 million a year ago. Basic loss per share from continuing operations was USD 0.77 compared to USD 1.61 a year ago.